Arvinas Inc ARVN

US Pharmaceuticals

$7.59 ▼ -2.57% ($-0.20)

Open $7.78

Prev Close $7.79

Day Range $7.54 – $7.81

52W Range $6.97 – $14.51

Market Cap $509.36M

P/E (TTM) 53.61

Beta 1.81

EPS (TTM) $0.16

📋 Company Profile

Industry	Pharmaceuticals
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2018-09-27
Shares Out.	64,520,000
Website	arvinas.com/ ↗
Phone	12035351456
Employees	246
Revenue	$249.7M
Gross Profit	$240.7M
Net Income	$169.4M
Free Cash Flow	-$208.8M
Total Assets	$675.1M
Total Liabilities	$112.9M
Equity	$562.2M

About Arvinas Inc

Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.

Arvinas Inc is a publicly traded company under the ticker symbol ARVN on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.